PAVmed exits the June quarter as a cleaned-up holdco whose residual claim still lives or dies on other people's milestones. The February recapitalization retired the old convertible stack and forced Series D into common, so the tape now prices a simpler equity. What it does not price away is a going-concern paragraph that sits on cash of just under four million and a senior note that still carries a fifteen percent coupon. Product sales at the parent remain a rounding error next to the cost of keeping Veris Health and a relaunched device incubator alive.
The economic engine is not the catalog. It is a management-services fee from Lucid Diagnostics that prints about three million every quarter, plus a Lucid equity stake marked near thirty-three million at mid-year. That mark already slipped from the March quarter close, and Lucid itself still waits on a Medicare local coverage determination for EsoGuard. Veris is the operating story the parent actually consolidates. Ohio State onboarding is live, yet parent revenue for the quarter was thirty-three thousand against operating costs above seven million.
The June print therefore tests a simple question. Can the parent keep Veris and the device incubator funded from Lucid fees and sporadic raises, or does the cash gap force another recap before Lucid coverage or a Veris clearance changes the funding math? Cash fell from the March quarter to mid-year by nearly three million. That burn rate is the clock.